EXACT Therapeutics AS (OSL: EXTX)
Norway flag Norway · Delayed Price · Currency is NOK
3.400
-0.060 (-1.73%)
At close: Jan 17, 2025

EXACT Therapeutics AS Company Description

EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT).

The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology and brain diseases.

The company’s ACT platform is under Phase I clinical trial for treatment of liver metastases; and pre-clinical studies for pancreatic, glioblastoma, and immunotherapy diseases, as well as CNS diseases and gene therapy.

EXACT Therapeutics AS has a collaboration with GE Healthcare for the development of a ready-to-use formulation of Sonazoid for ultrasound imaging and therapy; and with Agenus Inc. to develop proprietary immune checkpoint inhibitors in combination with EXACT’s Acoustic Cluster Technology, in pancreatic cancer.

The company was formerly known as Phoenix Solutions AS. EXACT Therapeutics AS was founded in 2012 and is based in Oslo, Norway.

EXACT Therapeutics AS
Country Norway
Founded 2012
Industry Biotechnology
Sector Healthcare
Employees 12
CEO Per Walday

Contact Details

Address:
Oestre Aker vei 19
Oslo, 0581
Norway
Website exact-tx.com

Stock Details

Ticker Symbol EXTX
Exchange Oslo Børs
Fiscal Year January - December
Reporting Currency NOK
ISIN Number NO0010852213
SIC Code 2836

Key Executives

Name Position
Dr. Per Walday Ph.D. Chief Executive Officer
Dr. Svein Kvåle Co Founder and Chief Operating Officer
John M. Edminson Chief Financial Officer
Dr. Masha Paule Nathalie Legris Stromme DPHIL Director
Dr. Amir Snapir M.D., Ph.D. Chief Medical Officer
Caspar Foghsgaard Chief Business Officer
Dr. Per Christian Sontum Founder
Ragnar Bendicksen Vice President of Technology